• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts use of insulin delivery device with physician-driven titration algorithm

November 26, 2018 By Sarah Faulkner

Valeritas V-Go device - updatedValeritas (NSDQ:VLRX) touted today the publication of a retrospective analysis showing that adults with Type 2 diabetes experienced improved glycemic control using the V-Go wearable insulin delivery device and a physician-driven titration algorithm.

The proof-of-concept study was designed to assess the safety and efficacy of a doctor-driven insulin titration algorithm in adults who were prescribed V-Go. Researchers evaluated the participants’ clinical outcomes after four months.

After four months of V-Go plus insulin dose adjustments with the algorithm, 67% of participants had an A1c level of less than 7.5% compared to 13% at baseline, according to Valeritas. The company also reported that the prevalence of hypoglycemia dropped to 7% after four months compared to 23% at baseline.

“Titration of insulin is an important step to improving glycemic control.  We are heartened by the impressive results demonstrated by combining a straightforward insulin titration algorithm with the simplicity of V-Go in patients with Type 2 diabetes to maximize results,” CEO John Timberlake said in prepared remarks.

Earlier this month, Valeritas priced a $36 million offering and posted its financial results for the third quarter, topping expectations on Wall Street.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS